Lucence shared a post on LinkedIn:
“Dr. Gilberto Lopes (GILBERTO de lima LOPES Junior), Chief of the Division of Medical Oncology and Associate Director for global oncology at Sylvester Comprehensive Cancer Center at the University of Miami, explores the evolving landscape of targeted therapy and how liquid biopsy — combining ctDNA and ctRNA analysis — supports personalized treatment planning.
Watch the full video here.
LiquidHALLMARK by Lucence is an ultra-sensitive liquid biopsy test that analyzes ctDNA and ctRNA to enable tailored treatment decisions.
Speak to your healthcare provider to seek advice on your options.”
Proceed to the video attached to the post.
More posts featuring Lucence on OncoDaily.